Navigation Links
Older and younger chronic leukemia patients may need different therapy
Date:12/12/2012

  • People who develop chronic lymphocytic leukemia (CLL) are typically age 65 and older, but participants in CLL clinical trials are usually several years younger;
  • The age of CLL patients is not usually considered when determining treatment;
  • This study suggests that older and younger CLL patients require different therapy.

COLUMBUS, Ohio Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.

The study was published Dec. 10 in the Journal of Clinical Oncology.

"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC James.

"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."

Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most

CLL clinical-trial participants are in their early 60s.

"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC James.

"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.

"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."

Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.

The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.

Key conclusions include:

  • Fludarabine versus chlorambucil: Fludarabine improved progression-free survival and overall survival among patients younger than age 70 but chlorambucil tended to produce higher overall survival in patients older than 70.
  • Rituximab combined with fludarabine, versus fludarabine alone, improves progression-free and overall survival in both younger and older patients.
  • Alemtuzumab consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Fear of falling may cause social isolation in older adults with vision problems
2. Maintaining weight loss as important as losing it for older women
3. Reduced intensity regimen prior to marrow transplant better for older leukemia patients
4. Paradox of aging: The older we get, the better we feel?
5. RI Hospital: Standardized road test results differ from older adults natural driving
6. Findings support safety of whooping cough vaccine for older adults
7. Long-Term Use of Some Antipsychotics Not Warranted in Older Adults: Study
8. Carbon Monoxide Poisoning Hazards Rise in Colder Weather
9. Heart failure in older breast cancer patients linked to medication
10. Smart drug improves survival in older patients with acute myeloid leukemia
11. Hip Surgery Increases Stroke Risk in Older Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: